Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Company Overview

Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore. Additional preclinical programs are directed toward addressing other metabolic disorders and infectious diseases. Arcturus’s research and development efforts focus on leveraging mRNA’s capacity for rapid design and production, aiming to reduce development timelines compared with traditional biologics.

Headquartered in San Diego, California, Arcturus maintains research and manufacturing facilities both in the United States and in Singapore, reflecting its commitment to global collaboration and supply chain resilience. The Singapore facility supports the company’s vaccine development programs and provides clinical-scale manufacturing capabilities to meet regulatory requirements in multiple jurisdictions.

Since going public in 2018, Arcturus has been led by Chief Executive Officer Joseph E. Payne, who brings experience from several biotechnology and pharmaceutical roles. Under his leadership, the company has forged partnerships with academic institutions and contract manufacturing organizations to advance its clinical programs. Arcturus continues to explore new applications of its mRNA platform through collaborations and licensing agreements aimed at expanding its pipeline and demonstrating the versatility of mRNA-based therapeutics.

Key Stats

• Today's Range: $5.64 to $5.96
• 50-Day Range: $5.53 to $8.04
• 52-Week Range: $5.50 to $24.17
• Volume: 266,582 shs
• Average Volume: 470,958 shs
• Market Capitalization: $163.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.25
• Consensus Rating: Moderate Buy

Arcturus Therapeutics Stock Analysis - MarketRank™

Arcturus Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 613th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcturus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Arcturus Therapeutics has a consensus price target of $24.25, representing about 322.8% upside from its current price of $5.74.

Amount of Analyst Coverage

Arcturus Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.99) to ($3.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcturus Therapeutics is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcturus Therapeutics is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcturus Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.98% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 10.71, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcturus Therapeutics has recently increased by 2.98%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcturus Therapeutics does not currently pay a dividend.

Dividend Growth

Arcturus Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.80

News Sentiment

Arcturus Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Arcturus Therapeutics this week, compared to 5 articles on an average week.

Search Interest

7 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

1 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 7/31/2026
• Next Earnings (Confirmed): 8/06/2026
• Canaccord Genuity's 46th Annual Growth Conference: 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARCT
• CIK: 1768224
• Web: www.arcturusrx.com
• Phone: (858) 900-2660
• Fax: N/A
• Employees: 180
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Arcturus Therapeutics: $24.25
• High Price Target: $54.00
• Low Price Target: $9.00
• Potential Upside/Downside: +326.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.78 million
• Net Margins: -143.80%
• Pretax Margin: -143.80%
• Return on Equity: -36.55%
• Return on Assets: -28.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.31
• Quick Ratio: 6.31

Sales & Book Value

• Annual Sales: $82.03 million
• Price / Sales: 1.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.53 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 28,420,000
• Free Float: 23,364,000
• Market Cap: $161.77 million
• Optionable: Optionable
• Beta: 2.37